Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study
4 affiliations
- 1The First Affiliated Hospital of Zhengzhou University
- 2The Second Clinical Medical College, Henan University of Chinese Medicine
- 3Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
- 4Department of Medical Oncology, Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine
Abstract
Objective: To compare pathological complete response (pCR) across different neoadjuvant treatment strategies in patients with locally advanced esophageal squamous cell carcinoma (ESCC) and to identify clinicopathological factors associated with pCR.
Methods: In this single-center retrospective cohort study, 247 consecutive patients with locally advanced ESCC who underwent neoadjuvant therapy followed by radical esophagectomy between January 2024 and June 2025 were included. Patients were categorized into four treatment groups: chemotherapy alone (CT, n = 50), chemoradiotherapy (CRT, n = 38), chemotherapy plus immunotherapy (CT+IO, n = 142), and chemoradiotherapy plus immunotherapy (CRT+IO, n = 17). Pathological complete response was defined as ypT0N0. Clinicopathological characteristics were compared using χ² or Fisher’s exact tests. Factors associated with pCR were evaluated using univariable and multivariable logistic regression analysis.
Results: Overall, 63 patients (25.5%) achieved pCR. The pCR rate was lower in the CT group than in the CT+IO group (6.0% vs. 26.8%). After adjustment for potential confounders, chemotherapy alone remained associated with lower odds of pCR than CT+IO (OR = 0.174, 95% CI, 0.046-0.658, P = 0.010). No significant differences were observed between CT+IO and either CRT or CRT+IO. Receipt of more than two neoadjuvant treatment cycles was associated with higher odds of pCR (OR = 2.764, 95% CI, 1.372-5.565, P = 0.004). Compared with cT3 disease, cT2 disease was associated with higher odds of pCR (OR = 3.049, 95% CI, 1.356-6.857, P = 0.007).
Conclusions: Neoadjuvant treatment regimen, the number of neoadjuvant treatment cycles, and pretreatment clinical T stage were associated with pathological complete response in locally advanced ESCC. Chemotherapy alone was associated with lower odds of pCR than CT+IO, whereas receipt of more than two treatment cycles was associated with higher odds of pCR. These findings provide real-world evidence regarding factors associated with pathological response.
Related
- Complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer and systemic oncologic benefit: a retrospective cohort study in Korea.
- Pathological complete response and long-term outcomes after neoadjuvant therapy for breast cancer: a multicenter retrospective cohort study with exploratory subtype analyses
- Immunoscore and Post-Neoadjuvant Pathological Features in Microsatellite-Stable Locally Advanced Gastric Cancer: A Retrospective Cohort Study
- A multimodal deep learning radiomics nomogram integrating clinicopathological features for predicting pathological complete response after neoadjuvant therapy in triple-negative breast cancer: a multicenter retrospective study
- Comparative effectiveness of preventive strategies against medically-attended respiratory syncytial virus in U.S. infants during the first six months of life, 2023-2025
BibTeX
@article{yuan2026comparative,
title = {{Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study}},
author = {Xiaoli Yuan and Yuying Liang and Tianlin Han and Zhilei Guo and Yue Sun and Yifan Dong and Lu Zhang and Huahua Li and Jia Li and Xu Sun and Huaimin Liu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1916194},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1916194/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study
AU - Xiaoli Yuan
AU - Yuying Liang
AU - Tianlin Han
AU - Zhilei Guo
AU - Yue Sun
AU - Yifan Dong
AU - Lu Zhang
AU - Huahua Li
AU - Jia Li
AU - Xu Sun
AU - Huaimin Liu
PY - 2026
DA - 2026/10/13
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1916194
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1916194/full
AB - Objective: To compare pathological complete response (pCR) across different neoadjuvant treatment strategies in patients with locally advanced esophageal squamous cell carcinoma (ESCC) and to identify clinicopathological factors associated with pCR. Methods: In this single-center retrospective cohort study, 247 consecutive patients with locally advanced ESCC who underwent neoadjuvant therapy followed by radical esophagectomy between January 2024 and June 2025 were included. Patients were categorized into four treatment groups: chemotherapy alone (CT, n = 50), chemoradiotherapy (CRT, n = 38), chemotherapy plus immunotherapy (CT+IO, n = 142), and chemoradiotherapy plus immunotherapy (CRT+IO, n = 17). Pathological complete response was defined as ypT0N0. Clinicopathological characteristics were compared using χ² or Fisher’s exact tests. Factors associated with pCR were evaluated using univariable and multivariable logistic regression analysis. Results: Overall, 63 patients (25.5%) achieved pCR. The pCR rate was lower in the CT group than in the CT+IO group (6.0% vs. 26.8%). After adjustment for potential confounders, chemotherapy alone remained associated with lower odds of pCR than CT+IO (OR = 0.174, 95% CI, 0.046-0.658, P = 0.010). No significant differences were observed between CT+IO and either CRT or CRT+IO. Receipt of more than two neoadjuvant treatment cycles was associated with higher odds of pCR (OR = 2.764, 95% CI, 1.372-5.565, P = 0.004). Compared with cT3 disease, cT2 disease was associated with higher odds of pCR (OR = 3.049, 95% CI, 1.356-6.857, P = 0.007). Conclusions: Neoadjuvant treatment regimen, the number of neoadjuvant treatment cycles, and pretreatment clinical T stage were associated with pathological complete response in locally advanced ESCC. Chemotherapy alone was associated with lower odds of pCR than CT+IO, whereas receipt of more than two treatment cycles was associated with higher odds of pCR. These findings provide real-world evidence regarding factors associated with pathological response.
SN - 2234-943X
ER -